John Volpone - 29 Oct 2025 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: President
Issuer ticker: XFOR
Reported as of: 29 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Oct 2025, 16:41:59 UTC
Prior SEC filing: 14 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ David Kirske, Attorney-In-Fact

Key filing fact

John Volpone filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 31 Oct 2025.

Key facts

This page summarizes John Volpone's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 31 Oct 2025, 16:41.

Change

Previous filing in this sequence was filed on 14 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002081729 Primary reporting owner

Volpone John

Relationship: President
Address: C/O X4 PHARMACEUTICALS INC., 61 NORTH BEACON STREET 4TH FLOOR, BOSTON
Signature: /s/ David Kirske, Attorney-In-Fact
Signature date: 31 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XFOR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +2,329,154
Change %
Price: $0.000000
Shares after: 2,329,154
Date: 29 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,329,154
Exercise price: $1.42
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.